Introduction
Over the last decade, transcatheter aortic valve replacement (TAVR) has emerged as an effective alternative to surgical replacement for patients with symptomatic severe aortic stenosis who are at high risk for surgery or are considered inoperable. 1, 2 The promising results of early randomized trials [1] [2] [3] have led to the use of this technology in intermediate-to low-risk patients, [4] [5] [6] with the first large randomized controlled trial showing non-inferiority of TAVR compared with surgical replacement. 7 Since these patients are often younger, valve durability has become an important concern. Recent studies have reported good durability of TAVR prostheses, for both balloon-and self-expandable valves, up to 5 years follow-up using transthoracic echocardiography. [8] [9] [10] [11] [12] However, sophisticated 3-and 4-dimensional computed tomography (CT) have described hypo-attenuated leaflet thickening (HALT) with reduced leaflet motion of TAVR prostheses, which could be an early marker of prosthetic valve thrombosis. [13] [14] [15] The effects of this leaflet thickening and restrictive motion on valve haemodynamics (assessed with echocardiography) and clinical outcome (transient ischemic attack or stroke) remain unclear and has led to ongoing debate on how to follow-up patients with TAVR valves and which antiplatelet/anticoagulation regime would be more appropriate. The present study aimed at evaluating the occurrence of abnormal valve haemodynamics (suggesting valve thrombosis) in both balloon-and self-expandable TAVR prostheses in a large patient cohort and compared these with the presence of HALT and/or reduced leaflet motion on dynamic multi-detector row CT (MDCT) data in a subpopulation. In addition, the clinical outcome (occurrence of ischemic stroke and/or transient ischemic attack [TIA] ) was assessed.
Methods Patient population and data collection
A total of 434 patients who underwent TAVR for severe aortic stenosis or degenerated biological aortic valve prosthesis between November 2007 and June 2015 at the Leiden University Medical Center were analyzed. Severe aortic stenosis was defined according to current recommendations: an aortic valve area <1.0 cm 2 or indexed aortic valve area <0.6 cm 2 /m 2 and mean transvalvular pressure gradient >40 mmHg. 16 The decision of TAVR was based on heart team discussions.
Patients were followed-up clinically at the outpatient clinic at 1-3, 6, and 12 months and thereafter yearly. A subgroup of 128 patients underwent post-procedural MDCT (median 35 days [interquartile range after TAVR) in the period of 2008-2013 as per institutional protocol (if there were no contraindications) and at the discretion of the treating cardiologist (see Supplementary material online, Figure S1 ).
Demographic and clinical data were collected using electronic records (EPD Vision, version 11.4.29.0, EPD Vision, Leiden, The Netherlands). TAVR success and complications were registered as defined by the Valve Academic Research Consortium-2 (VARC-2). 17 After the procedure, all patients received aspirin life long, whereas clopidogrel was prescribed for 3 months between 2007 and 2011 and thereafter for 1 month. If concomitant oral anticoagulants were used, aspirin was not prescribed. The institutional review board approved this retrospective analysis of clinically acquired data and waived the need for patient written informed consent.
Transcatheter aortic valve replacement procedure TAVR was performed via transfemoral access, if adequate iliofemoral arterial anatomy was present as assessed with pre-procedural MDCT, or via transapical access otherwise. Transcatheter valve size was selected based on MDCT measurements of the aortic annulus, as previously described. 18 Contemporary balloon-and self-expandable valve prostheses were used: Edwards SAPIEN, SAPIEN XT, SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA), and the Medtronic CoreValve system (Medtronic, MN, Minnesota). Implantation procedures were performed under general anaesthesia with fluoroscopy and transesophageal echocardiography guidance. The haemodynamics of the implanted transcatheter valve were assessed immediately. If significant paravalvular or, less frequently, transvalvular regurgitation were noted, reballooning of the prosthesis or valve-in-valve implantation were performed, respectively.
Echocardiographic follow-up
Transthoracic echocardiography was performed at discharge, 6 and 12 months and yearly thereafter (up to 3 years) to assess the transcatheter valve haemodynamics over time. Commercially available ultrasound systems equipped with 3.5 MHz or M5S transducers (Vivid-7 or E9 systems, General Electric Vingmed, Horten, Norway) were used and 2-dimensional, colour, continuous, and pulsed wave Doppler data were acquired from parasternal and apical views with the patient in the left lateral decubitus position. Images were stored digitally on hard disks for offline analysis (EchoPac version BT13; GE Medical Systems). Left ventricular ejection fraction was measured from the apical 2-and 4-chamber views using Simpson's method. 19 Aortic valve peak jet velocity was estimated from the continuous wave Doppler recordings obtained on the 3-or 5-chamber apical views and, if needed, on the right parasternal view using the Pedoff probe. 16 The peak and mean transaortic pressure gradients were calculated according to the Bernoulli equation. The aortic valve area was calculated using the continuity equation. According to current recommendations, abnormal transcatheter aortic valve haemodynamics indicating valve stenosis caused probably by thrombosis was based on a mean transvalvular gradient > _20 mmHg and an aortic valve area < _1.1 cm 2 . 20 The presence of paravalvular leakage at follow-up was graded using a multiparametric approach that integrates valve structure and motion, regurgitant flow characteristics including the circumferential extent of the paravalvular leak and left ventricular dimensions, as recommended by the VARC-2 criteria. 17 
Multi-detector row computed tomographic follow-up
Using a 64-row (Aquilion 64; Toshiba Medical Systems, Tochigi-ken, Japan) or a 320-row (AquilionOne; Toshiba Medical Systems, Tochigiken, Japan) CT scanners, electrocardiographic-gated and contrastenhanced data acquisition of the aortic root was performed using previously described protocols. 21, 22 MDCT data were reconstructed at each 10% of RR-interval of the cardiac cycle. All data sets were analysed using dedicated post-processing software (Vitrea FX 6.5; Vital Images, Minnetonka, MN). The structure and motion of the transcatheter valve leaflets were assessed. Structural assessment focused on the presence of HALT, frame eccentricity and expansion, and transcatheter implantation depth. HALT was defined as hypo-attenuated thickening with or without reduced motion of one or more transcatheter valve leaflets and was assessed by 2-dimensional multiplanar reformation planes, and 3-and 4-dimensional volume rendered movies throughout the entire cardiac cycle (Figure 1 ). mid-portion, and outflow) by using planimetered outer stent area and minimal and maximal diameters as described earlier. 13, 15 An expansion ratio of < _90% of nominal stent dimensions at all three levels was defined as underexpansion. Non-circularity of the transcatheter frame was defined as an eccentricity index >0.1 at all three levels, with eccentricity index calculated as 1 -(minimal diameter/maximal diameter). 13, 15 In addition, implant depth was measured and defined as the distance between the aortic annular plane and lower transcatheter valve prosthesis rim.
Clinical endpoints at follow-up
Patients were followed-up prospectively at the outpatient clinic of the Leiden University Medical Centre at 1-3, 6, and 12 months follow-up after TAVR, and yearly thereafter (at the referral centre). Patients with suspected neurologic events were evaluated by a neurologist. For this specific analysis, the occurrence of ischemic stroke (including TIA and ischemic stroke) was recorded. 
Statistical analysis

Results
Patient population
Baseline clinical, echocardiographic, and procedural characteristics for the overall population (mean age 80 ± 7 years, 51% male) are shown in Table 1 . Anticoagulant medication (vitamin K antagonists) was used in 37% of the patients, while 52% used aspirin and 33% clopidogrel. Baseline transthoracic echocardiography showed severe aortic stenosis (mean transvalvular gradient 42.3 ± 18.1 mmHg, aortic valve area 0.78 ± 0.28 cm 2 ) and mean LVEF 53.9 ± 16.1%. The majority of the patients had tricuspid anatomy of the aortic valve, 21 (5%) had a bicuspid aortic valve and 13 (3%) patients underwent valve-invalve procedure. TAVR access was transfemoral in 52% of the patients and the remaining 48% underwent transapical TAVR. The most frequently implanted prosthesis size was 26 mm (54%). The majority of the patients received a balloon-expandable transcatheter valve (91%), whereas 40 patients received a self-expandable prosthesis. At Table S1 .
Abnormal valve haemodynamics on echocardiography at follow-up
During the follow-up period, transthoracic echocardiography was performed in 431 patients at hospital discharge, in 350 patients at 6 months follow-up, in 229 patients at 1-year follow-up and in 116 and 61 patients at 2 and 3 years follow-up, respectively. After TAVR, a significant decrease in transvalvular gradients (peak gradient: from 65.5 ± 26.5 mmHg to 17.1 ± 8.1 mmHg, P < 0.001; mean gradient: from 42.3 ± 18.1 mmHg to 9.3 ± 4.7 mmHg, P < 0.001) and an increase in aortic valve area (from 0.78 ± 0.28 cm 2 to 1.99 ± 0.56 cm 2 , P < 0.001) were observed. Table 2 and Figure 2 present the haemodynamic changes of TAVR prostheses over time for the overall population. The peak and mean transvalvular gradients remained unchanged. However, the aortic valve area showed a statistically significant decrease after hospital discharge until 1 year follow-up, with a maximum decrease to 1.61 ± 0.51 cm 2 . In addition, a significant increase in LVEF was noted (from 53.9 ± 16.1% to 57.5 ± 14.7%, P < 0.001) (Figure 2 ).
According to current recommendations, abnormal valve haemodynamics (mean transvalvular gradient > _20 mmHg and aortic valve area < _1.1 cm 2 ) indicating possible transcatheter valve thrombosis were observed in 1 (0.2%) patient before discharge, 6 (2%) patients at 6 months, 4 (2%) at 1 year, 0 (0%) patients at 2 years, and 2 (3%) at 3 years follow-up. Worsening of paravalvular or transvalvular regurgitation to moderate regurgitation was observed in 17 (4%) patients at follow-up.
HALTor reduced leaflet motion on MDCT at follow-up
In a subgroup of 128 patients with analysable post-TAVR MDCT data, the presence of HALT and/or reduced leaflet motion was evaluated. The MDCT data were acquired at a median interval of 35 [interquartile range ] days after TAVR (see Supplementary ma terial online, Figure S1 ). The presence of HALT and/or reduced leaflet motion was noted in 16 (12.5%) patients. Baseline clinical, echocardiographic, and procedural characteristics between patients showing HALT and/or reduced leaflet motion and patients without are presented in Tables 3 and 4 . There were no statistically significant differences between both groups with the exception of diabetes mellitus which was more prevalent among patients without HALT compared to patients with HALT and/or reduced leaflet motion (32% vs. 6%, respectively; P = 0.033). Importantly, there were no differences in anticoagulation use prior to MDCT (38 [30%] in the overall group, 35 [31%] in patients without HALT and 3 [19%] patients with HALT and/or reduced leaflet motion, P = 0.603). Table 5 shows the post-TAVR MDCT characteristics in patients with and without HALT. Both groups were comparable in terms of stent expansion, eccentricity index at the inflow and outflow levels of the stent and valve im- 
Correlation between abnormal valve haemodynamics and HALT
Concomitant presence of HALT and/or reduced leaflet motion and abnormal valve haemodynamics (defined by mean transvalvular gradient > _20 mmHg and aortic valve area < _1.1 cm 2 ) suggesting valve thrombosis was observed in only one patient (Figure 1) . Figure 3 presents the changes in echocardiographic parameters of transcatheter valve function at follow-up in patients with HALT on MDCT and patients without. Patients showing HALT and/or reduced leaflet motion on post-TAVR MDCT had higher peak and mean transvalvular gradients and smaller aortic valve area at follow-up as compared with patients without, but the difference was statistically significant only for the mean transvalvular gradient at 6 months follow-up (12.4 ± 8.0 mmHg vs. 9.4 ± 4.3 mmHg, respectively; P = 0.026) and for the aortic valve area at the echocardiogram performed at the time of MDCT (1.49 ± 0.39 cm 2 vs. 1.78 ± 0.45 cm 2 , respectively; P = 0.017) and at 6 months (1.32 ± 0.35 cm 2 vs. 1.76 ± 0.49 cm 2 , respectively; P < 0.001). LVEF was comparable in both groups without significant differences over time. Similarly, both groups were comparable in terms of paravalvular regurgitation grade over time.
Correlation between stroke and echocardiographic/MDCT findings
A total of 14 (3.2%) patients were diagnosed with stroke (n = 9)/TIA (n = 5) after TAVR. Possible transcatheter aortic valve thrombosis on echocardiography (mean transvalvular gradient > _20 mmHg and aortic valve area < _1.1cm 2 ) was not present in any of the patients diagnosed with stroke/TIA. Similarly, HALT and/or reduced leaflet motion was not observed on MDCT in any of the patients presenting with stroke/TIA. Table 6 shows the mean and peak transvalvular gradients, aortic valve area, and LVEF over time for patients with vs. without stroke/TIA. There were no differences in valve haemodynamics between patients with and without stroke/TIA ( Table 6) .
Discussion
The present study showed stable, normal haemodynamics and morphological features of transcatheter aortic valves during mid-term follow-up in a large cohort of patients treated with TAVR indicating good mid-term durability of these prosthetic valves. Only a mild, clinically irrelevant, decrease in aortic valve area was observed during the first year post-TAVR, while average transvalvular gradients remained within the normal range. Possible transcatheter valve thrombosis based on abnormal valve haemodynamics on echocardiography was rare (3% of patients at 3 years follow-up). Post-TAVR MDCT showed HALT and/or reduced leaflet motion in 12.5% of patients. In patients with HALT and/or reduced leaflet motion, echocardiographic transvalvular gradients were slightly higher and the aortic valve area was significantly smaller compared with patients without HALT. However, possible TAVR valve thrombosis by MDCT (presence of HALT and/or reduced leaflet motion) was only accompanied by abnormal valve haemodynamics on echocardiography (mean ) in one patient. These abnormal findings were not associated with an increased risk of ischemic stroke/TIA.
Echocardiographic valve haemodynamics after TAVR
Since TAVR is increasingly used as an alternative for surgical aortic valve replacement in intermediate-and low-risk patients, valvular prosthesis durability and structural integrity are important issues. Thrombosis of biological surgical aortic valves is a rare complication with a reported incidence ranging between 0.8% and 4%. 23, 24 In transcatheter aortic valve prostheses, the reported incidence of valve dysfunction and specifically thrombosis is low. showed only a slight increase of mean transvalvular gradient (12.8 ± 10.9 mmHg) 5 years after self-expanding transcatheter valve implantation in 353 high-risk patients. Late prosthesis failure occurred in 1.4% and it was defined as symptomatic prosthesis stenosis, endocarditis, and severe transvalvular or paravalvular regurgitation. Mild prosthesis stenosis, defined by a mean gradient between 20 and 40 mmHg, was observed in 2.8% of patients. 8 Data from a multicentre study including 1521 patients treated with self-expandable (49.7%) and balloon-expandable prostheses (48.5%) reported an incidence of structural valve degeneration of 4.5% at 2 years of followup. 25 The relatively high incidence of valve degeneration in that registry compared with previous studies can be explained by the definition itself: absolute increase in mean transvalvular gradient > _10 mmHg. An increase in mean transvalvular gradient > _10 mmHg during followup can be caused by changes in loading conditions, stroke volume, or increase in body mass index leading to increased prosthesis-patient mismatch and not necessarily because of valve thrombosis or stenosis. Current recommendations define transcatheter aortic valve stenosis potentially caused by valve thrombosis when the mean transvalvular gradient is > _20 mmHg and the aortic valve area is < _1.1cm 2 on echocardiography. 20 In the present study, aortic valve area and transvalvular aortic gradients remained stable during 3 years follow-up and 3% of the population showed abnormal valve haemodynamics at 3 years follow-up, consistent with previous studies. Therefore, based on echocardiographic criteria, transcatheter aortic valves appear to have good durability.
HALT and/or abnormal leaflet motion on MDCT, and relation with echocardiographic valve haemodynamics
The high-spatial resolution of MDCT data has shown that abnormal leaflet motion with apposition of hypo-attenuated masses (HALT) in surgical and transcatheter valves may be more frequent than expected. Leetmaa 13 whereas use of anticoagulation has been associated with lower prevalence of HALT. 14 Importantly, adding anticoagulants to antiplatelet therapy resolved HALT and reduced leaflet motion rapidly. 15 Other procedural factors such as prosthesis frame deployment were not associated with HALT. 14, 15 Nevertheless, the relation between HALT and valve haemodynamics at short-and long-term follow-up remains unclear. The majority of the patients showing HALT did not have increased mean transvalvular gradients > _20 mmHg or decreased aortic valve area < _1.1cm 2 (the echocardiographic definitions of possible prosthetic valve thrombosis). [13] [14] [15] 26 In the present study, the incidence of HALT on MDCT was 12.5%, comparable with previous studies. 13, 15, 26 The patients with HALT had a slightly more circular deployment of the transcatheter valve frame compared with those without HALT. The present study provides additional information by reporting transcatheter aortic valve haemodynamics at mid-term follow-up. Although there was a mild change in valve haemodynamics with an increase in both mean and peak transvalvular gradients and a significant decrease in aortic valve area in patients with HALT and/or reduced leaflet motion shortly after TAVR compared with their counterparts, concomitant mean transvalvular gradient > _20 mmHg and aortic valve area < _1.1cm 2 was anecdotally observed during the 3 years of follow-up (1 patient). Therefore, the HALT and/or reduced leaflet motion on MDCT was not accompanied by functional echocardiographic criteria of thrombosis.
Clinical implications of HALT
While surgical prosthetic aortic valve thrombosis is associated with an increased risk of stroke, 23, 24 this association is not consistently observed with the presence of HALT on transcatheter aortic valve prostheses. [13] [14] [15] The reported rates of stroke and TIA in the Cohort A PARTNER trial ranged from 5.5% to 8.3% at 30 days and 1-year follow-up, respectively, and to 15.9% at 5 years follow-up. 3, 11 In the NOTION (Nordic Aortic Valve Intervention) trial, randomizing low surgical risk patients to TAVR or surgical aortic valve replacement, the rates of stroke and TIA were, respectively, 2.9% and 2.1% at 1-year follow-up. 6 In these trials, no structural valve degeneration was observed and valve haemodynamics remained stable over time. Therefore, these results suggest that the source of stroke/TIA may not primarily be related to the transcatheter valve or that the echocardiographic findings may not be sensitive enough to detect early structural changes of the valve before they present with increased gradients and that can cause embolic events. The use of MDCT showing the presence of HALT and reduced leaflet motion of transcatheter valves has questioned these assumptions. Similar to previous studies, patients in the present study who showed HALT and/or reduced leaflet motion on MDCT did not develop stroke/TIA at follow-up. However, the use of anticoagulation has been shown to restore the normal leaflet aspect and motion in patients who presented with HALT 14, 15 and it could be considered to perform MDCT in these patients for early detection of these structural changes.
TAVR thrombosis: HALT, valve haemodynamics, and stroke However, it remains unknown when and in whom the MDCT should be performed and if it should be systematically included in the surveillance of TAVR patients. The important associated risks of MDCT such as renal deterioration associated with the use of contrast and cumulative radiation should be weighed against the risk of stroke/TIA in elderly patients with associated comorbidities and, in the future, in younger patients. Current guidelines recommend transthoracic echocardiography within 6 weeks-3 months after implantation of bioprostheses, when there are changes in the clinical symptoms or signs of valve dysfunction and yearly after 5-10 years of bioprosthesis implantation even if there are no changes in the patient's clinical condition. 27, 28 Specific recommendations for follow-up in patients treated with TAVR have not been defined yet. The cumulative evidence provided by registries and ongoing randomized clinical trials will have an impact on current recommendations.
27,28
Study limitations
Several limitations should be acknowledged. This was a retrospective, single-centre study. MDCT after TAVR was performed in a relatively small subgroup of patients. This may have introduced a selection bias. In addition, the findings observed on the MDCT scans relate to previous generations of transcatheter valves and may not be generalizable to newer aortic valve prostheses (Edwards SAPIEN 3 and Medtronic CoreValve Evolut R). Furthermore, the vast majority of patients received a balloon-expandable prosthesis. Patients who deceased during follow-up may have died due to transcatheter valve thrombosis which may underestimate the true incidence of this complication. Assessment of reduced leaflet motion with MDCT may be challenging due to the low temporal resolution of the technique.
Conclusion
Transcatheter aortic valves showed good mid-term durability with low rates of abnormal valve haemodynamics at 3 years follow-up. The rate of possible valve thrombosis based on echocardiographic criteria was low (3% at 3 years follow-up). MDCT detected HALT and/or reduced leaflet motion in 12.5% of patients. Only one patient with HALT presented with abnormal valve haemodynamics (the echocardiographic criterium of valve thrombosis). Importantly, both HALT and abnormal valve haemodynamics were not associated with increased risk of ischemic stroke/TIA in the current population.
